GSK Dividends and Buybacks
Dividend criteria checks 2/6
GSK is a dividend paying company with a current yield of 4.32%. Next payment date is on 9th January, 2025 with an ex-dividend date of 15th November, 2024.
Key information
4.3%
Dividend yield
-0.04%
Buyback Yield
| Total Shareholder Yield | 4.3% |
| Future Dividend Yield | 5.1% |
| Dividend Growth | -1.9% |
| Next dividend pay date | 09 Jan 25 |
| Ex dividend date | 15 Nov 24 |
| Dividend per share | US$0.735 |
| Payout ratio | 99% |
Recent dividend and buyback updates
Recent updates
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
Dec 11GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
Oct 26GSK's Q2 Success Amid Challenges: What Investors Need To Know
Aug 26GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)
Jul 31GSK Breathes New Life Into Asthma Treatment With Depemokimab
May 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: GSK's dividend payments have been volatile in the past 10 years.
Growing Dividend: GSK's dividend payments have fallen over the past 10 years.
Dividend Yield vs Market
| GSK Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GSK) | 4.3% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (GSK) (up to 3 years) | 5.1% |
Notable Dividend: GSK's dividend (4.32%) is higher than the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: GSK's dividend (4.32%) is low compared to the top 25% of dividend payers in the US market (4.53%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (98.9%), GSK's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (48.1%), GSK's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:09 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GSK plc is covered by 62 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |